ARMATA PHARMACEUTICALS, INC. Convertible Debt, Noncurrent
ARMATA PHARMACEUTICALS, INC. (ARMP) had Convertible Debt, Noncurrent of $254.92 million as of 2026-03-31, per its 10-Q filed 2026-05-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Long-Term Debt, Excluding Current Maturities
us-gaap:ConvertibleDebtNoncurrent · last filed 2026-08-12
- 2026-03-31: Convertible Debt, Noncurrent $254.92M.
- 2025-12-31: Convertible Debt, Noncurrent $153.86M.
- 2024-12-31: Convertible Debt, Noncurrent $32.90M.
- 2023-12-31: Convertible Debt, Noncurrent $58.63M.
| Period end | Convertible Debt, Noncurrent |
|---|---|
| 2026-03-31 | $254.92M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $153.86M 10-Q · filed 2026-08-12 |
| 2024-12-31 | $32.90M 10-K · filed 2026-03-25 |
| 2023-12-31 | $58.63M 10-K · filed 2025-03-21 |
| 2023-09-30 | $49.75M 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |